Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20
4:51
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Lymphoma Similar Videos
-
Virtual Challenging Case Clinic: B-cell Lymphomas_Diffuse Large B-cell Lymphoma_Julie Vose, MD, MBA
47:20
-
IUCLS 2023 Saturday Morning General Session_Sonali Smith, MD, FASCO_Andrew Evens, DO, MBA, MSc_Timothy Fenske, MD, MS
8:39
-
Virtual Challenging Case Clinic: B-cell Lymphomas_Updates from ASH_Sonali Smith, MD, FASCO
50:40